Docetaxel – July 2007

Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion, 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®, July 2005.

  • Brand names:
    • Taxotere®
  • Pharmaceutical Company:
    • Sanofi-Aventis Group
  • Condition/Indication: Androgen Independent (Hormone Refractory) prostate cancer
  • Meeting Date: July 2005
Last updated
27 June 2025